| Autor: |
Harinder Gill, Rita Yim, Herbert H. Pang, Paul Lee, Thomas S. Y. Chan, Yu‐Yan Hwang, Garret M. K. Leung, Ho‐Wan Ip, Rock Y. Y. Leung, Sze‐Fai Yip, Bonnie Kho, Harold K. K. Lee, Vivien Mak, Chi‐Chung Chan, June S. M. Lau, Chi‐Kuen Lau, Shek‐Yin Lin, Raymond S. M. Wong, Wa Li, Edmond S. K. Ma, Jun Li, Gianni Panagiotou, Joycelyn P. Y. Sim, Albert K. W. Lie, Yok‐Lam Kwong |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Cancer Medicine, Vol 9, Iss 10, Pp 3371-3382 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2045-7634 |
| DOI: |
10.1002/cam4.2865 |
| Popis: |
Abstract Clofarabine is active in refractory/relapsed acute myeloid leukemia (AML). In this phase 2 study, we treated 18‐ to 65‐year‐old AML patients refractory to first‐line 3 + 7 daunorubicin/cytarabine induction or relapsing after 3 + 7 induction and high‐dose cytarabine consolidation, with clofarabine (30 mg/m2/d, Days 1‐5), cytarabine (750 mg/m2/d, Days 1‐5), and mitoxantrone (12 mg/m2/d, Days 3‐5) (CLAM). Patients achieving remission received up to two consolidation cycles of 50% CLAM, with eligible cases bridged to allogeneic hematopoietic stem cell transplantation (allo‐HSCT). The mutational profile of a 69‐gene panel was evaluated. Twenty‐six men and 26 women at a median age of 46 (22‐65) years were treated. The overall response rate after the first cycle of CLAM was 90.4% (complete remission, CR: 69.2%; CR with incomplete hematologic recovery, CRi: 21.2%). Twenty‐two CR/CRi patients underwent allo‐HSCT. The 2‐year overall survival (OS), relapse‐free survival (RFS), and event‐free survival (EFS) were 65.8%, 45.7%, and 40.2%, respectively. Multivariate analyses showed that superior OS was associated with CR after CLAM (P = .005) and allo‐HSCT (P = .005), and superior RFS and EFS were associated with allo‐HSCT (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
